Background-The age, creatinine, and ejection fraction (ACEF) score (age/left ventricular ejection fractionϩ1 if creatinine Ͼ2.0 mg/dL) has been established as an effective predictor of clinical outcomes in patients undergoing elective coronary artery bypass surgery; however, its utility in "all-comer" patients undergoing percutaneous coronary intervention is yet unexplored. Methods and Results-The ACEF score was calculated for 1208 of the 1707 patients enrolled in the LEADERS trial. Post hoc analysis was performed by stratifying clinical outcomes at the 1-year follow-up according to ACEF score tertiles: ACEF low Յ1.0225, 1.0225Ͻ ACEF mid Յ1.277, and ACEF high Ͼ1.277. At 1-year follow-up, there was a significantly lower number of patients with major adverse cardiac event-free survival in the highest tertile of the ACEF score (ACEF low ϭ92.1%, ACEF mid ϭ89.5%, and ACEF high ϭ86.1%; Pϭ0.0218). Cardiac death was less frequent in ACEF low than in ACEF mid and ACEF high (0.7% vs 2.2% vs 4.5%; hazard ratioϭ2.22, Pϭ0.002) patients. Rates of myocardial infarction were significantly higher in patients with a high ACEF score (6.7% for ACEF high vs 5.2% for ACEF mid and 2.5% for ACEF low ; hazard ratioϭ1.6, Pϭ0.006). Clinically driven target-vessel revascularization also tended to be higher in the ACEF high group, but the difference among the 3 groups did not reach statistical significance. The rate of composite definite, possible, and probable stent thrombosis was also higher in the ACEF high group (ACEF low ϭ1.2%, ACEF mid ϭ3.5%, and ACEF high ϭ6.2%; hazard ratioϭ2.04, PϽ0.001). Conclusions-ACEF score may be a simple way to stratify risk of events in patients treated with percutaneous coronary intervention with respect to mortality and risk of myocardial infarction. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00389220. (Circ Cardiovasc Interv. 2011;4:47-56.)
S everal validated risk assessment scores such as the EuroSCORE have been developed for mortality risk assessment in cardiac surgery. 1 More recently, these simple scores incorporating patient clinical characteristics have also been applied to patients undergoing percutaneous coronary interventions (PCI). [2] [3] [4] In a recent study, Romagnoli et al 3 reported an area under the receiver operating characteristic (ROC) curve of 0.91 for in-hospital mortality among 1173 patients treated with PCI, indicating a good discriminatory power of the EuroSCORE in patients undergoing PCI. A novel and even simpler score has been proposed and tested in patients undergoing coronary artery bypass graft surgery incorporating age, creatinine, and ejection fraction (ACEF score). 5 The advantage of this simplified risk model is that it avoids the problem of "overfitting" to many independent variables when applied to populations with low numbers of events. In patients undergoing isolated coronary artery bypass graft surgery, the ACEF score calculated by age/ejection fractionϩ1 (if creatinine Ͼ2.0 mg/dL) had an area under the ROC curve of 0.826, which was higher than that of more complex risk scores. To our knowledge, the performance of the ACEF score to predict event rates and cardiac mortality has not been tested in patients undergoing PCI. In this post hoc analysis of the "all-comers" LEADERS trial, 6 we assessed the value of the ACEF score in predicting major adverse cardiac events (MACEs) at 1-year follow-up. In addition, we have compared its predictive value for events with that of the SYNTAX score 7 and have assessed the additive value of both scores (the so-called clinical SYNTAX score). Finally, we aimed to test whether the ACEF and combined ACEF*SYNTAX scores performed as well in this all-comers population undergoing PCI as they did in the multivessel-disease patient populations undergoing coronary artery bypass graft surgery and/or PCI, for which they were initially developed and applied (shrinkage phenomenon). 8
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Methods
Study Population
LEADERS was a European multicenter, noninferiority trial comparing the safety and efficacy of the BioMatrix Flex biolimuseluting stent with a biodegradable polymer (Biosensors, Morges, Switzerland) with the CypherSelect sirolimus-eluting stent with a durable polymer (Cordis, NJ) in 1707 all-comer patients. Details of the study protocol can be found in the main article. 6 The study complied with the Declaration of Helsinki and was approved by all institutional ethics committees. All patients provided written, informed consent for participation in the trial.
ACEF Score and Analysis
The ACEF score was calculated according to the following formula: ACEFϭage/left ventricular ejection fractionϩ1 (if creatinine was Ͼ2.0 mg/dL). 5 Patients were divided into tertiles based on the ACEF score. A modified clinical SYNTAX score was calculated by multiplying the ACEF score by the SYNTAX score.
Study End Points
Definitions of all end points are provided elsewhere. 6 The primary end point of this substudy was MACEs, defined as the composite of cardiac death, myocardial infarction (MI), and clinically indicated target-vessel revascularization (TVR) within 12 months. Secondary end points were any target lesion revascularization (TLR) (both clinically and nonclinically indicated), any TVR, cardiac death, death from any cause, MI, stent thrombosis (defined according to the Academic Research Council 9 ), device success, and lesion success.
Statistical Analysis
A stratified post hoc analysis of clinical and angiographic outcomes was performed according to tertiles of the ACEF score. All randomized patients were included in the analysis. Angiographic outcomes were analyzed by SAS v8 Proc Mixed for continuous and Proc Genmod for binomial outcomes, taking into account the within-patient correlation structure of these data. The Cox proportional-hazards model was used to compare clinical outcomes between the groups. All analyses were performed with SAS 8.02 by a dedicated statistician. All probability values and confidence intervals were 2-sided. The multivariate model included ACEF score, diabetes, ␤-blocker use, stent type, and presence of acute coronary syndrome/ST-segment elevation MI as covariates. Testing for (linear) trend was done by using generalized linear models with ACEF class as a covariable for continuous variables and the Cochran-Armitage test for trend in categorical data. C-statistics and ROC curves were constructed to assess the ability of the ACEF score and ACEF*SYNTAX score (modified clinical SYNTAX score) to predict events. 10
Results
ACEF Score and Baseline Characteristics
The ACEF score could be calculated retrospectively for 1208 of the 1707 patients enrolled in the trial. We were unable to calculate the score for 499 patients owing to the unavailability of renal function assessment or ejection fraction (mostly in patients presenting with ST-segment elevation MI). The score ranged from 0.562 to 5.403, with a meanϮSD of 1.278Ϯ0.539 and a median of 1.131 (interquartile range of 0.964 to 1.398). In this post hoc analysis, the ACEF score tertiles were defined as follows: ACEF low , Ͻ1.0225 (nϭ404); 1.0225Յ ACEF mid Յ1.277 (nϭ402), and ACEF high Ͼ1.277 (nϭ402). Baseline clinical and angiographic characteristics of the patients are listed in Tables 1 through 4. In addition to differences in age and the presence of renal insufficiency (creatinine Ͼ2.0 mg/ dL) among the 3 tertiles of ACEF score, patients with higher ACEF scores were more likely to be female, have diabetes, smoke, have hypertension, have a prior history of MI, have concomitant peripheral vascular disease, and present with an unstable coronary syndrome. Conversely, patients with low ACEF scores were more likely to be hypercholesterolemic, have a family history of heart disease, and were more likely to present with stable angina or ST-segment elevation MI. The 3 groups did not differ significantly with respect to angiographic characteristics except for a slightly higher number of lesions, a trend for a greater number of stents implanted, and a significantly greater number of lesions with moderate to severe calcification. All 51 patients with renal insufficiency were in the high-ACEF-score group. Thus, the ACEF score calculation for the low and mid ACEF tertiles was age/left ventricular function.
One-Year Outcomes
The ACEF score significantly predicted the rate of MACEs and cardiac death, as well as the rate of MI at 360 days (Tables 5 and 6 and Figures 1 through 4 ). There was a significantly lower number of patients with MACE-free survival in the highest tertile of the ACEF score (ACE-F low ϭ92.1%, ACEF mid ϭ89.5%, and ACEF high ϭ86.1%; Pϭ0.0218). The composite end point of cardiac death, MI, and TVR occurred in 7.9% of ACEF low patients, 10.4% of patients with ACEF mid scores, and 13.9% of ACEF high patients (hazard ratio [HR]ϭ1.34, PϽ0.007). Cardiac death occurred in 0.7% of patients with low ACEF scores, 2.2% of patients with intermediate ACEF scores, and 4.5% of patients with high ACEF scores (HRϭ2.22, Pϭ0.002). The rate of MI was significantly higher in patients with high ACEF scores (6.7% for ACEF high vs 5.2% for ACEF mid and 2.5% for ACEF low ; HRϭ1.6, Pϭ0.006).
Clinically driven TVR also tended to be higher in the ACEF high group, but the difference among the 3 groups did not reach statistical significance (ACEF low ϭ5.4%, ACEF mid ϭ6.5%, and ACEF high ϭ8%; HRϭ1.22, Pϭ0.16). The rate of composite definite, possible, and probable stent thrombosis was also higher in the high-ACEF group (ACEF low ϭ1.2%, ACEF mid ϭ3.5%, and ACEF high ϭ6.2%; HRϭ2.04, PϽ0.001). Patients treated with biolimus-and sirolimus-eluting stents had equivalent event rates across all 3 ACEF tertiles.
Multivariate Model
In a multivariate model, the ACEF score remained a significant predictor of MACEs and mortality (Tables 5  and 6 ; note that the HRs are adjusted for the following variables: ACEF score, diabetes, ␤-blocker use, stent type, and presence of ST-segment elevation MI/acute coronary syndrome, the same variables used in the assessment of the predictive value of the SYNTAX score in the LEADERS trial). 7 Patients in the ACEF high group had a 34% higher risk of the composite end point of cardiac death, MI, and clinically indicated TVR than did patients in the ACEF mid group (Pϭ0.007), which was comparable to the 60% higher composite event rate among diabetics (Pϭ0.012). Use of a biolimus-eluting stent conferred a nonsignificant 12% reduction in events and with ␤-blocker use, a 16% reduction was observed, but there was no difference in events due to acute coronary syndrome presentation.
C-Statistics for ACEF Score and ACEF*SYNTAX Score
The ACEF score c-statistic values for predicting cardiac death and the occurrence of MI were 0.727 and 0.615, respectively, in this all-comers patient population (Table 7) . This compares favorably with SYNTAX score c-statistics of 0.647 for cardiac death and 0.561 for MI in the same population of the LEADERS trial. Conversely, the ACEF score's ability to assess the risk of overall MACEs and TVR was lower (0.577 and 0.527, respectively). The SYNTAX score in the same population was a better predictor of MACEs and TVR, with c-statistics of 0.61 and 0.58, respectively. Combining the ACEF with the SYNTAX score in the modified clinical SYNTAX score (ACEF*SYNTAX score) resulted in improvement in area under the ROC curves for MACEs (from 0.577 to 0.618) and TLR (0.527 to 0.575; Table 7 ). However, the area under the ROC curves for cardiac death and MI decreased after combining the SYNTAX score with the ACEF score. 
Discussion
With the rapidly expanding indications for PCI and the concomitant increasing age and clinical complexity of patients undergoing these procedures, risk assessment with respect to overall MACE rate and particularly mortality rate has become a very important aspect of daily clinical decision making. Multiple risk-assessment models have been developed for surgical patients and are starting to be used increasingly in the assessment of patients undergoing PCIs, particularly when decisions are needed with respect to the appropriateness of surgical versus percutaneous revascularization in patients with extensive coronary artery disease and multiple comorbidities. Some of these risk scores, such as SYNTAX, have excellent prognostic value 7, [11] [12] [13] but are based solely on anatomic information and only indirectly incorporate clinical characteristics, in so far as patients who are older and have renal insufficiency tend to also have more calcified vessels and more diffuse disease. Many of the surgical risk models incorporate too many variables, which results in inaccuracies and the overfitting associated with them; in addition, some models incorporate several patient characteristics that impart high risk to surgical patients only but not necessarily to patients undergoing PCI. The ACEF score, though only currently validated in a surgical patient group, is simple and easy to calculate and combines 3 important clinical characteristics, namely, age, creatinine (renal insufficiency), and left ventricular ejection fraction. 5 As such, it is extremely useful and applicable to patients undergoing PCI. In this substudy of the all-comers LEADERS trial, which well reflects the real-world population of patients being treated in tertiary PCI centers, we tested for the first time the predictive value of the ACEF score for MACEs. Indeed, the ACEF score appears highly predictive of cardiac death and MI risk. It is less robust in its ability to predict the overall composite primary end point, which is largely due to the lower ability to assess the risk of repeat revascularization. We have recently performed an analysis on the ability of the SYNTAX score to predict events in the LEADERS study. 7 Figure 2 . A, Kaplan-Meier score for cardiac death at 360 days according to ACEF score tertiles. B, Kaplan-Meier score for cardiac death at 360 days according to ACEF*SYNTAX score tertiles.
Compared with the ACEF score, the SYNTAX score was better at predicting overall MACEs and the risk of repeat revascularization. However, the ACEF score was a better model to predict risk of cardiac death and MI. The use of the ACEF and SYNTAX score in combination in this all-comers patient population with a median ACEF score of 1.131 and a median SYNTAX score of 12 did not result in a better explanatory model for risk assessment, which is likely to be the result of the low number of events and the aforementioned overfitting. This finding contrasts with our analysis performed in the higher-risk multivessel-disease population enrolled in the ARTS-II study, who had a median SYNTAX score of 19 and a modified ACEF score of 1.1, wherein the combination of the 2 scores in the so-called clinical SYNTAX score resulted in higher c-statistics and better predictive values for both mortality and overall MACEs at 5 years of follow-up. 14 In summary, this first assessment of the performance of the ACEF score as a risk model to predict cardiac death and MI in an all-comers population of patients undergoing PCI with drug-eluting stents appears adequate. One may consider using anatomically based scores, such as SYNTAX, to more accurately assess the risk of repeat revascularization. The combination of these 2 scores may be needed in particularly challenging and high-risk patient populations, such as those with multivessel disease, to improve the accuracy of risk prediction. In addition, the SYNTAX score is better validated in guiding the treatment choice of coronary artery bypass graft versus PCI. 11, 12 On the other hand, the ACEF score is composed of objectively measured variables, whereas the SYNTAX score assessment involves a subjective evaluation of an angiogram, which may be prone to interobserver variability. 15, 16 
Limitations
We acknowledge that this substudy suffers from the limitations of post hoc analysis. In addition, the ACEF score has not been previously validated in patients undergoing PCI, and further validation will be necessary in a larger cohort of patients from a pooling of multiple PCI studies. Lastly, the follow-up in this substudy of LEADERS and thus assessment of the predictive value of the ACEF score are limited to 1 year. In one third of patients, the ACEF score could not be calculated owing to missing creatinine or ejection fraction values (mostly in patients presenting with ST-segment elevation MI).
CLINICAL PERSPECTIVE
Risk stratification is becoming an increasingly important part of the assessment of patients who are candidates for coronary revascularization. We have recently reported that the SYNTAX score, which was initially developed for risk assessment in patients with multivessel disease, is also predictive of major cardiovascular events in an all-comers patient population undergoing percutaneous coronary intervention. The SYNTAX score, which is based entirely on the extent of coronary disease, has its limitations and does not take into account important clinical variables that may also influence outcomes. The ACEF score, defined as age/left ventricular ejection fractionϩ1 (if creatinine Ͼ2.0 mg/dL), was initially validated in a cohort of patients undergoing bypass surgery and incorporates important clinical factors. In the current study, we demonstrate that this simple score is also a valid predictor of outcomes in an all-comers patient population undergoing percutaneous coronary intervention. The combination of the 2 scores may be particularly useful in very clinically complex patients, enabling physicians to provide an individualized assessment of risk, which is vital for appropriate informed consent. 
